Clinical Trials for Prinicipal Investigator: Daniela Bota

9 Open Trials. Phone:(877.827.8839)
Protocol No. Title Status
ECOG-EAY131 (CIRB) Molecular Analysis for Therapy Choice (MATCH) Open
SWOG-S1609 (CIRB) DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Open
UCI-12-18 (BIOREPOSITORY PROTOCOL) Comprehensive, Coordinated Clinical, Imaging and Histological Database for the Study of Neurological Outcomes of Cancer and Cancer Treatments Open
UCI-13-14 A Randomized, Double-blinded, Placebo-controlled Phase 2 study of (ERC1671/ GM-CSF / Cyclophosphamide) + Bevacizumab vs. (Placebo Injection / Placebo pill) + Bevacizumab in the treatment of recurrent/progressive, Bevacizumab naïve glioblastoma multiforme and gliosarcoma patients (WHO grade IV malignant gliomas) Open
UCI-15-35 A Phase 2/3 Randomized, Open Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma Open
UCI-15-99 Open-label, non-randomized, phase 2 study evaluating efficacy and safety of PQR309 in patients with relapsed or refractory primary CNS lymphoma Open
UCI-16-54 Identification of functional MRI, neuropsychiatric, and circulating VEGF changes after marizomib treatment in patients enrolled in the UCI 14-58 study (single agent marizomib cohort) Open
UCI-16-55 Phase 1b, Multicenter, Open-Label Study of Marizomib with Temozolomide and Radiotherapy in Patients with Newly Diagnosed WHO Grade IV Malignant Glioma Open
UCI-17-91 [EXEMPTED] Compassionate Use study of ICT-107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemotherapy Open